Analyst Price Target is $121.50
▲ +19.14% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Novartis in the last 3 months. The average price target is $121.50, with a high forecast of $130.00 and a low forecast of $114.00. The average price target represents a 19.14% upside from the last price of $101.98.
Current Consensus is
Reduce
The current consensus among 9 polled investment analysts is to reduce stock in Novartis. This rating has held steady since August 2024, when it changed from a Hold consensus rating.
Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Read More